bepridil has been researched along with sertraline in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Fry, EE; Ren, J; Stuart, DI; Zhao, Y | 1 |
| Bavari, S; Besch, R; Duplantier, AJ; Jay, WB; Kota, KP; Kuehl, K; Lazić, M; Mudhasani, R; Panchal, RG; Pavić, A; Retterer, C; Sean, VA; Selaković, Ž; Šolaja, BA; Soloveva, V; Tran, JP; Vasiljević, B; Verbić, T | 1 |
| Alonso, C; Campillo, NE; Cuesta-Geijo, MÁ; Delgado, R; Gil, C; Ginex, T; Morales-Tenorio, M; Muñoz-Fontela, C | 1 |
| Chen, W; Han, S; Hu, Y; Li, H; Tong, X; Yang, L; Zuo, J | 1 |
| Delos, SE; DeWald, LE; Glass, PJ; Grenier, JM; Hensley, LE; Hoffstrom, BG; Johansen, LM; Lear-Rooney, CM; Lehár, J; Nelson, E; Olinger, GG; Pajouhesh, H; Pierce, LT; Shoemaker, CJ; Simmons, JA; Stossel, A; White, JM | 1 |
1 review(s) available for bepridil and sertraline
| Article | Year |
|---|---|
Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
Topics: Antibodies; Ebolavirus; Glycoproteins; Hemorrhagic Fever, Ebola; Humans; Molecular Docking Simulation; Niemann-Pick C1 Protein; Protein Binding; Small Molecule Libraries; Virus Internalization | 2021 |
11 other study(ies) available for bepridil and sertraline
| Article | Year |
|---|---|
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Ebolavirus; Glycoproteins; Hemorrhagic Fever, Ebola; Models, Molecular; Protein Conformation; Thermodynamics; Vero Cells; Virus Internalization | 2018 |
Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
Topics: Animals; Antiviral Agents; Chrysenes; Ebolavirus; Hemorrhagic Fever, Ebola; Lysosomes; Mice; Surface-Active Agents; Virus Internalization; Zebrafish | 2019 |
Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
Topics: Antiviral Agents; Ebolavirus; Hemorrhagic Fever, Ebola; HIV Fusion Inhibitors; Humans; Molecular Docking Simulation; Virus Internalization | 2022 |
A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.
Topics: Animals; Antiviral Agents; Bepridil; Drug Approval; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Mice; Molecular Probes; Sertraline | 2015 |